YOLFTbeta
Hualan Biological EngineeringInc

Hualan Biological EngineeringInc

002007 · SHE · Healthcare / Biotechnology

11.78CNY-0.22 (-1.83%)

Price History

Full chart

Market Stats

Previous Close12.00
Open12.02
Day Range11.75 – 12.03
52-Week Range11.72 – 16.37
Volume11.32M
Market Cap24.35B
P/E (TTM)30.32
Forward P/E24.57
EPS0.44
Dividend Yield9.22%
Beta0.37
50-Day Avg13.16
200-Day Avg14.19

About

Hualan Biological Engineering Inc., together with its subsidiaries, engages in the research, development, production, and sale of biological products in China and internationally. The company offers blood products, including human serum albumin, human prothrombin complex concentrate, human coagulation factor VIII, human fibrinogen, and freeze-dried human fibrin glue for surgical use, as well as intravenous, human, rabies, hepatitis B, and tetanus immunoglobulin for various therapeutic applications. It also provides vaccine products, such as influenza virus split, H1N1 influenza A virus split, quadrivalent influenza virus split, group A and C meningococcal polysaccharide, group ACYW135 meningococcal polysaccharide, recombinant hepatitis B vaccine, freeze-dried human rabies, and adsorbed tetanus vaccines. In addition, the company develops monoclonal antibody drugs and biosimilars comprising rituximab injection which is in Phase III clinical trials for the treatment of CD20-positive diffuse large B-cell/follicular non-Hodgkin lymphoma and chronic lymphocytic leukemia; adalimumab injection which is in Phase III clinical trials for the treatment of various autoimmune diseases; denosumab injection which is in Phase III clinical trials for the treatment of patients with bone metastases; injectable trastuzumab which is in Phase III clinical trials for the treatment of HER2-positive metastatic/early-stage breast cancer and metastatic gastric cancer; and recombinant Exendin-4-FC fusion protein injection which is in Phase I/II clinical trials for the treatment of type 2 diabetes. Further, it is involved in the research and development of poultry farming; plasma collection; engineering technology research and experimental development; and inspection and testing services. The company was founded in 1992 and is headquartered in Xinxiang, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Bei Fan
  • Employees4.12K
  • HeadquartersNo. 1, Hualan Avenue, Xinxiang, China, 453003, China
  • Websitehttps://www.hualanbio.com

Leadership

  • Ms. Bei FanGM & Director · b. 1972
  • Ms. Ping LinCFO & Accounting Supervisor
  • Mr. Bao Xian ZhangDeputy GM & Director · b. 1971
  • Mr. Yuancheng LouBoard Secretary · b. 1984
  • Mr. Xiao Wei MaExecutive Deputy General Manager · b. 1968
  • Ms. Jun LiuDeputy General Manager · b. 1976
  • Mr. Zhengyue ChenDeputy General Manager · b. 1961

Financials

Income Statement

Currency: CNY2001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue124.37M172.66M252.91M320.79M361.28M352.99M351.14M475.16M1.22B1.26B961.40M972.46M1.12B1.24B1.47B1.93B2.37B3.22B3.70B5.02B4.44B4.52B5.34B4.38B4.58B
Growth (%)-+38.83%+46.48%+26.84%+12.62%-2.29%-0.53%+35.32%+156.86%+3.37%-23.80%+1.15%+14.93%+11.26%+18.36%+31.45%+22.41%+35.84%+15.02%+35.76%-11.69%+1.82%+18.26%-18.02%+4.49%
Cost of Revenue86.14M114.30M162.89M222.60M241.20M216.11M162.31M189.43M292.84M294.11M286.25M423.65M467.18M489.25M644.49M773.83M921.25M1.12B1.35B1.40B1.54B1.70B1.73B1.77B2.06B
Gross Profit38.23M58.36M90.02M98.19M120.08M136.88M188.83M285.73M927.66M967.51M675.14M548.81M650.43M754.24M827.27M1.16B1.45B2.09B2.35B3.62B2.90B2.82B3.61B2.61B2.51B
Gross Margin30.74%33.80%35.59%30.61%33.24%38.78%53.78%60.13%76.01%76.69%70.23%56.44%58.20%60.66%56.21%60.00%61.10%65.03%63.62%72.03%65.33%62.38%67.67%59.62%54.90%
Operating Expense19.87M24.35M47.61M46.87M60.24M42.32M63.09M64.10M135.95M167.68M235.22M247.84M112.38M170.59M158.91M323.13M530.89M700.56M738.58M1.47B1.20B1.39B1.52B1.23B1.38B
Operating Income18.36M34.01M42.41M51.32M59.84M94.56M125.74M221.63M791.71M799.83M439.92M300.97M538.05M583.65M668.36M837.71M916.03M1.39B1.62B2.15B1.70B1.42B2.10B1.38B1.13B
Operating Margin14.76%19.70%16.77%16.00%16.56%26.79%35.81%46.64%64.87%63.40%45.76%30.95%48.14%46.94%45.41%43.30%38.68%43.25%43.65%42.81%38.24%31.54%39.28%31.50%24.68%
EBITDA23.15M37.64M55.43M64.96M76.00M115.47M164.96M269.66M832.42M887.92M540.59M395.22M563.86M621.61M691.94M922.89M976.59M1.33B1.60B2.18B1.78B1.50B2.07B1.44B1.41B
EBITDA Margin18.62%21.80%21.92%20.25%21.04%32.71%46.98%56.75%68.20%70.38%56.23%40.64%50.45%49.99%47.01%47.70%41.24%41.30%43.12%43.38%40.18%33.12%38.74%32.86%30.84%
Net Income15.45M28.85M35.49M41.36M52.54M79.00M120.43M187.26M608.48M612.36M370.72M299.79M475.34M538.42M589.12M780.31M820.82M1.14B1.28B1.61B1.30B1.08B1.48B1.09B940.40M
Net Income Margin12.42%16.71%14.03%12.89%14.54%22.38%34.30%39.41%49.85%48.54%38.56%30.83%42.53%43.30%40.03%40.33%34.66%35.42%34.69%32.11%29.28%23.83%27.74%24.84%20.55%
R&D---------56.14M44.20M63.80M59.81M56.08M69.43M98.64M129.41M146.46M143.54M213.21M253.63M314.70M280.84M333.18M295.82M
R&D as % of Total Revenue---------4.45%4.60%6.56%5.35%4.51%4.72%5.10%5.46%4.55%3.88%4.24%5.72%6.97%5.26%7.61%6.46%
Interest Expense5.10M3.90M5.91M8.81M2.24M4.00M5.96M9.84M1.58M186.37K234.48K3.35M7.93M3.97M157.61K212.11K05.88M7.08M5.41M22.06M30.64M13.46M13.44M10.79M
Interest Expense % of Total Revenue4.10%2.26%2.34%2.75%0.62%1.13%1.70%2.07%0.13%0.01%0.02%0.34%0.71%0.32%0.01%0.01%0.00%0.18%0.19%0.11%0.50%0.68%0.25%0.31%0.24%

Balance Sheet

Currency: CNY2001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets195.12M241.56M348.52M644.01M699.99M816.57M958.23M1.26B2.01B2.58B2.73B2.96B3.64B3.77B4.02B4.65B5.22B6.49B7.58B10.04B11.54B14.74B16.11B16.31B15.26B
Total Liabilities130.09M147.47M218.79M143.53M149.20M227.67M288.51M117.50M155.67M170.06M153.99M131.84M332.55M133.70M137.11M215.05M377.24M720.47M699.26M1.94B2.47B2.53B2.68B2.46B1.81B
Total Equity65.02M94.10M129.74M500.48M526.23M555.73M639.98M1.10B1.66B2.17B2.37B2.60B3.08B3.40B3.66B4.22B4.67B5.53B6.54B7.53B8.34B10.40B11.36B11.86B11.50B
Cash26.25M29.17M48.61M226.23M199.05M201.59M149.35M291.95M704.31M1.08B884.50M747.95M1.04B672.06M363.27M486.00M205.99M427.89M1.06B1.04B692.54M1.10B993.77M1.37B774.81M
Total Debt90.00M90.55M150.00M55.00M24.00M140.00M150.00M-----150.00M------400.00M990.70M1.11B709.50M908.51M547.20M
Net Debt63.75M61.38M101.39M-171.23M-175.05M-61.59M653.39K-291.95M-704.31M-1.08B-884.50M-747.95M-885.31M-672.06M-363.27M-486.00M-205.99M-427.89M-1.06B-638.33M298.16M11.04M-284.27M-458.15M-227.61M

Cash Flow

Currency: CNY2001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow--3.35M21.48M98.24M131.43M179.02M161.18M607.73M609.53M335.93M494.69M510.70M497.15M548.62M329.94M177.42M1.29B1.36B1.33B1.43B957.31M1.35B1.06B1.14B
Investing Cash Flow---32.80M-86.71M-76.66M-212.28M-213.92M-126.82M-159.49M-149.65M-322.09M-565.98M-368.13M-471.93M-514.56M19.28M-55.91M-844.29M-844.97M-739.39M-1.76B-2.45B-998.28M90.08M270.27M
Financing Cash Flow--48.90M242.84M-55.14M77.74M-17.14M108.26M-35.97M-84.04M-210.36M-67.50M142.04M-380.95M-348.78M-232.52M-397.04M-221.14M-340.76M-226.20M35.89M1.92B-454.96M-780.43M-2.00B
Capital Expenditure0032.82M22.00M58.59M217.30M213.92M126.90M162.43M149.67M143.59M147.15M249.21M139.21M229.34M220.66M108.54M183.26M272.95M621.44M811.35M393.95M753.41M255.79M197.31M
Free Cash Flow---29.47M-517.10K39.65M-85.87M-34.90M34.28M445.30M459.87M192.34M347.54M261.49M357.94M319.29M109.28M68.88M1.11B1.09B703.85M621.15M563.36M592.43M803.92M944.67M
Dividends Paid--5.91M7.23M27.25M46.33M42.14M9.93M43.72M95.54M172.86M72.50M57.62M236.16M348.78M232.52M397.04M275.26M390.65M561.34M564.11M364.87M563.64M467.83M1.36B
FCF to OCF---880.83%-2.41%40.36%-65.34%-19.50%21.27%73.27%75.45%57.26%70.25%51.20%72.00%58.20%33.12%38.83%85.82%79.97%53.11%43.36%58.85%44.02%75.89%82.72%
Dividend Paid to FCF---20.04%-1398.90%68.72%-53.95%-120.74%28.96%9.82%20.78%89.87%20.86%22.04%65.98%109.24%212.78%576.40%24.81%35.85%79.75%90.82%64.77%95.14%58.19%144.12%

Earnings

Report DateAug 27, 2009Jun 2, 2010Sep 1, 2010Dec 1, 2010Mar 2, 2011Jun 1, 2011Aug 31, 2011Nov 30, 2011Feb 29, 2012May 30, 2012Aug 29, 2012Nov 28, 2012Feb 27, 2013May 29, 2013Aug 28, 2013Oct 28, 2013Feb 24, 2014May 28, 2014Jul 31, 2014Oct 30, 2014Mar 27, 2015Apr 22, 2015Aug 26, 2015Oct 29, 2015Feb 29, 2016Apr 27, 2016Aug 17, 2016Oct 26, 2016Feb 27, 2017Apr 26, 2017Aug 20, 2017Oct 19, 2017Feb 27, 2018Apr 26, 2018Aug 26, 2018Oct 29, 2018Feb 25, 2019Apr 25, 2019Aug 29, 2019Oct 27, 2019Feb 28, 2020Apr 7, 2020Aug 10, 2020Oct 30, 2020Mar 10, 2021Apr 29, 2021Aug 29, 2021Oct 29, 2021Mar 29, 2022Apr 28, 2022Aug 22, 2022Oct 30, 2022Mar 29, 2023Apr 21, 2023Aug 23, 2023Oct 29, 2023Mar 29, 2024Apr 25, 2024Aug 29, 2024Oct 29, 2024Mar 28, 2025Apr 27, 2025Aug 27, 2025Oct 28, 2025Mar 27, 2026Apr 26, 2026Aug 28, 2026
EPS Estimate0.03--------------0.050.06--0.070.08--0.11-0.090.200.120.100.230.110.170.180.120.140.100.180.160.170.220.240.180.190.320.270.170.230.330.390.140.150.280.250.170.090.410.200.130.130.340.160.140.110.310.240.170.11
EPS Actual0.020.120.060.090.080.070.050.050.030.070.020.030.040.070.060.070.050.100.060.070.050.080.090.080.070.090.230.100.080.280.090.140.140.110.140.150.210.130.050.250.180.130.080.230.360.140.110.330.130.130.190.170.100.190.100.300.190.140.080.250.090.170.110.150.090.130.08
Surprise-33.33%--------------40.00%-16.67%--0.00%-37.50%---27.27%-0.00%15.00%-16.67%-20.00%21.74%-18.18%-17.65%-22.22%-8.33%0.00%50.00%16.67%-18.75%-70.59%13.64%-25.00%-27.78%-57.89%-28.13%33.33%-17.65%-52.17%0.00%-66.67%-7.14%26.67%-39.29%-60.00%11.76%11.11%-26.83%-5.00%7.69%-38.46%-26.47%-43.75%21.43%0.00%-51.61%-62.50%-23.53%-27.27%
TimingAfter-hours--------------After-hoursAfter-hours-Pre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-market

Key Statistics & Ratios

Market Cap24.35B
Enterprise Value21.45B
Trailing P/E30.32
Forward P/E24.57
PEG Ratio1.34
Price / Sales5.58
Price / Book2.21
EPS0.44
Book Value6.01
Revenue (TTM)4.36B
Gross Profit (TTM)2.36B
EBITDA1.23B
Profit Margin18.52%
Operating Margin14.66%
Return on Equity6.54%
Return on Assets3.99%
Shares Outstanding1.83B
Shares Float961.32M
Beta0.37
Dividend Yield9.22%
Dividend Rate1.20
Payout Ratio2.22%

Dividends

20261×
0.50Jun 15, 2026
20252×
0.50Oct 27, 20250.20Jun 17, 2025
20241×
0.30Jun 14, 2024
20231×
0.30Jun 14, 2023
20221×
0.20Jun 16, 2022
20211×
0.30Jun 23, 2021
20201×
0.40Apr 27, 2020
20191×
0.21Jun 17, 2019
20181×
0.15Jun 27, 2018
20171×
0.21Jun 13, 2017
20161×
0.13Jun 7, 2016
20151×
0.19Jun 5, 2015
20141×
0.13Jun 20, 2014
20131×
0.03Jun 24, 2013
20121×
0.04Jul 13, 2012
20111×
0.10Jun 16, 2011
20101×
0.04May 27, 2010
20091×
0.03May 6, 2009
20071×
0.02Oct 24, 2007
20061×
0.02May 8, 2006
20051×
0.01May 23, 2005

Stock Splits

  • Apr 27, 20201.3:1
  • Jun 17, 20191.5:1
  • Jun 7, 201616:10
  • May 27, 20101.6:1
  • May 6, 200916:10
  • Oct 24, 200712:10
  • Jun 12, 20071.2:1
  • Oct 20, 20061.5:1
  • May 23, 200515:10